| Cell-laden microengineered pullulan methacrylate hydrogels promote cell proliferation and 3D cluster formation H Bae, AF Ahari, H Shin, JW Nichol, CB Hutson, M Masaeli, SH Kim, ... Soft matter 7 (5), 1903-1911, 2011 | 136 | 2011 |
| Evidence for cerebrospinal fluid entry into the optic nerve via a glymphatic pathway E Mathieu, N Gupta, A Ahari, X Zhou, J Hanna, YH Yücel Investigative ophthalmology & visual science 58 (11), 4784-4791, 2017 | 131 | 2017 |
| Development of functional biomaterials with micro‐and nanoscale technologies for tissue engineering and drug delivery applications H Bae, H Chu, F Edalat, JM Cha, S Sant, A Kashyap, AF Ahari, CH Kwon, ... Journal of tissue engineering and regenerative medicine 8 (1), 1-14, 2014 | 97 | 2014 |
| Directed assembly of cell-laden hydrogels for engineering functional tissues NN Kachouie, Y Du, H Bae, M Khabiry, AF Ahari, B Zamanian, J Fukuda, ... Organogenesis 6 (4), 234-244, 2010 | 95 | 2010 |
| Surface-modified hyaluronic acid hydrogels to capture endothelial progenitor cells G Camci-Unal, H Aubin, AF Ahari, H Bae, JW Nichol, A Khademhosseini Soft matter 6 (20), 5120-5126, 2010 | 79 | 2010 |
| Reduced cerebrospinal fluid inflow to the optic nerve in glaucoma E Mathieu, N Gupta, LA Paczka-Giorgi, X Zhou, A Ahari, R Lani, J Hanna, ... Investigative Ophthalmology & Visual Science 59 (15), 5876-5884, 2018 | 54 | 2018 |
| Microengineering hydrogels for stem cell bioengineering and tissue regeneration I Wheeldon, AF Ahari, A Khademhosseini JALA: Journal of the Association for Laboratory Automation 15 (6), 440-448, 2010 | 42 | 2010 |
| Evaluation of Crohn disease activity using a potential abbreviated MRE protocol consisting of balanced steady-state free precession MRI only versus full-protocol MRE KS Jhaveri, S Sagheb, L Guimaraes, S Krishna, AF Ahari, O Espin-Garcia American Journal of Roentgenology 216 (2), 384-392, 2021 | 14 | 2021 |
| Intralesional injection of bone marrow aspirate concentrate for the treatment of osteonecrosis of the knee secondary to systemic lupus erythematosus: a case report D Kouroupis, AF Ahari, D Correa, R Shammaa Frontiers in bioengineering and biotechnology 8, 202, 2020 | 14 | 2020 |
| An automated two-phase system for hydrogel microbead production DF Coutinho, AF Ahari, NN Kachouie, ME Gomes, NM Neves, RL Reis, ... Biofabrication 4 (3), 035003, 2012 | 11 | 2012 |
| Injectable hydrogels for personalized cancer immunotherapies N Mohaghegh, A Ahari, F Zehtabi, C Buttles, S Davani, H Hoang, K Tseng, ... Acta Biomaterialia 172, 67-91, 2023 | 10 | 2023 |
| Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma RF Riedel, V Chua, A Moradkhani, N Krkyan, A Ahari, A Osada, ... The Oncologist 27 (10), 809-e765, 2022 | 3 | 2022 |
| Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311) SP Chawla, WA Tellez, H Chomoyan, C Valencia, A Ahari, N Omelchenko, ... Frontiers in Oncology 13, 1116937, 2023 | 2 | 2023 |
| Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma. N Omelchenko, NS Chawla, S Makrievski, G Leao De Melo, C Valencia, ... Journal of Clinical Oncology 41 (16_suppl), 11555-11555, 2023 | 1 | 2023 |
| Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma. NS Chawla, N Omelchenko, E Younesi, C Valencia, A Ahari, ... Journal of Clinical Oncology 41 (16_suppl), 11556-11556, 2023 | 1 | 2023 |
| GALLANT: A phase 2 study using metronomic gemcitabine, doxorubicin, nivolumab, and docetaxel as second/third-line therapy for advanced sarcoma (NCT04535713). N Adnan, S Sekhon, SP Chawla, TT Kim, VS Chua-Alcala, M Fernando, ... Journal of Clinical Oncology 40 (16_suppl), 11518-11518, 2022 | 1 | 2022 |
| Injectable Shear‐Thinning Hydrogels with Sclerosing and Matrix Metalloproteinase Modulatory Properties for the Treatment of Vascular Malformations F Zehtabi, A Gangrade, K Tseng, R Haghniaz, R Abbasgholizadeh, ... Advanced Functional Materials 33 (51), 2305880, 2023 | | 2023 |
| 1925P Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma NS Chawla, N Omelchenko, S Makrievski, GL De Melo, D Brigham, ... Annals of Oncology 34, S1035, 2023 | | 2023 |
| 1980P Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor … SP Chawla, N Omelchenko, C Eid, S Jeffrey, Z Shekhovtsova, ... Annals of Oncology 34, S1056-S1057, 2023 | | 2023 |
| Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy. EM Gordon, N Omelchenko, C Eid, S Jeffrey, Z Shekhovtsova, ... Journal of Clinical Oncology 41 (16_suppl), e15083-e15083, 2023 | | 2023 |
Ali KhademhosseiniTerasaki Institute, Amazon, Harvard, MITE-mail megerősítve itt: terasaki.org
